HRS/EHRA/APHRS/LAHRS/ACC/AHA worldwide practice update for telehealth and arrhythmia monitoring during and after a pandemic

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), started in the city of Wuhan late in 2019. Within a few months, the disease spread toward all parts of the world and was declared a pandemic on March 11, 2020. The current health care dilemma worldwide is how to sustain the capacity for quality services not only for those suffering from COVID-19 but also for non-COVID-19 patients, all while protecting physicians, nurses, and other allied health care workers.

[1]  David R. Holtgrave,et al.  Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State , 2020, The Journal of Emergency Medicine.

[2]  G. Hripcsak,et al.  Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 , 2020, The New England journal of medicine.

[3]  Michael A. Spinelli,et al.  QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin , 2020, Heart Rhythm.

[4]  L. Epstein,et al.  Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection , 2020, Circulation. Arrhythmia and electrophysiology.

[5]  M. Ueda,et al.  Remote Management of Pacemaker Patients With Biennial In-Clinic Evaluation , 2020, Circulation. Arrhythmia and electrophysiology.

[6]  Nathaniel Hupert,et al.  Clinical Characteristics of Covid-19 in New York City , 2020, The New England journal of medicine.

[7]  D. Mann,et al.  COVID-19 Clinical Trials , 2020, JACC: Basic to Translational Science.

[8]  M. Eslami,et al.  Transient complete heart block in a patient with critical COVID-19 , 2020, European heart journal.

[9]  Erwan L'Her,et al.  Compassionate Use of Remdesivir for Patients with Severe Covid-19 , 2020, The New England journal of medicine.

[10]  C. Tondo,et al.  Cardiac and arrhythmic complications in patients with COVID‐19 , 2020, Journal of cardiovascular electrophysiology.

[11]  J. Healey,et al.  Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society , 2020, Canadian Journal of Cardiology.

[12]  P. Noseworthy,et al.  Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19) , 2020, Mayo Clinic Proceedings.

[13]  L. Epstein,et al.  Inpatient use of mobile continuous telemetry for COVID-19 patients treated with hydroxychloroquine and azithromycin , 2020, HeartRhythm Case Reports.

[14]  Reyma Raju,et al.  How to protect the protectors: 10 lessons to learn for doctors fighting the COVID-19 coronavirus , 2020, Medical Journal Armed Forces India.

[15]  Zhan Zhang,et al.  Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial , 2020, medRxiv.

[16]  Roberto Maroldi,et al.  Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). , 2020, JAMA cardiology.

[17]  Tao Guo,et al.  Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) , 2020, JAMA cardiology.

[18]  X. Bian,et al.  [A pathological report of three COVID-19 cases by minimally invasive autopsies]. , 2020, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[19]  J. Hollander,et al.  Virtually Perfect? Telemedicine for Covid-19. , 2020, The New England journal of medicine.

[20]  K. Kim,et al.  What Is COVID-19? , 2020, Frontiers for Young Minds.

[21]  Shao-hua Hu,et al.  Online mental health services in China during the COVID-19 outbreak , 2020, The Lancet Psychiatry.

[22]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[23]  T. Bunch,et al.  HRS White Paper on interoperability of data from cardiovascular implantable electronic devices (CIEDs). , 2019, Heart Rhythm.

[24]  P. Sager,et al.  Assessment of Multi‐Ion Channel Block in a Phase I Randomized Study Design: Results of the CiPA Phase I ECG Biomarker Validation Study , 2019, Clinical pharmacology and therapeutics.

[25]  N. White,et al.  The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review , 2018, BMC Medicine.

[26]  D. Yoon,et al.  Risk Evaluation of Azithromycin-Induced QT Prolongation in Real-World Practice , 2018, BioMed research international.

[27]  Aarti S. Dalal,et al.  Can smartphone wireless ECGs be used to accurately assess ECG intervals in pediatrics? A comparison of mobile health monitoring to standard 12-lead ECG , 2018, PloS one.

[28]  L. Epstein,et al.  Factors Influencing the Decision to Proceed to Firmware Upgrades to Implanted Pacemakers for Cybersecurity Risk Mitigation. , 2018, Circulation.

[29]  Peter J. Schwartz,et al.  A wearable remote monitoring system for the identification of subjects with a prolonged QT interval or at risk for drug-induced long QT syndrome. , 2018, International journal of cardiology.

[30]  C. Omarini,et al.  Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus , 2018, BioMed research international.

[31]  G. Tomlinson,et al.  Electrocardiogram abnormalities related to anti-malarials in systemic lupus erythematosus. , 2018, Clinical and experimental rheumatology.

[32]  Wojciech Zareba,et al.  2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. , 2017, Heart rhythm.

[33]  G. Hindricks,et al.  Daily remote monitoring of implantable cardioverter-defibrillators: insights from the pooled patient-level data from three randomized controlled trials (IN-TIME, ECOST, TRUST) , 2017, European heart journal.

[34]  Long Chen,et al.  Electrophysiologic Studies on the Risks and Potential Mechanism Underlying the Proarrhythmic Nature of Azithromycin , 2017, Cardiovascular Toxicology.

[35]  B. Lindsay,et al.  Association Between Off-site Central Monitoring Using Standardized Cardiac Telemetry and Clinical Outcomes Among Non-Critically Ill Patients. , 2016, JAMA.

[36]  Dwight Reynolds,et al.  Comparison of QT Interval Readings in Normal Sinus Rhythm Between a Smartphone Heart Monitor and a 12‐Lead ECG for Healthy Volunteers and Inpatients Receiving Sotalol or Dofetilide , 2016, Journal of cardiovascular electrophysiology.

[37]  Haipeng Xiao,et al.  The Role of Macrolide Antibiotics in Increasing Cardiovascular Risk. , 2015, Journal of the American College of Cardiology.

[38]  R. Ohannessian,et al.  Telemedicine: Potential applications in epidemic situations , 2015, European Research in Telemedicine / La Recherche Européenne en Télémédecine.

[39]  Renato Pietro Ricci,et al.  HRS Expert Consensus Statement on remote interrogation and monitoring for cardiovascular implantable electronic devices. , 2015, Heart rhythm.

[40]  J. Sin,et al.  Azithromycin and the Risk of Cardiovascular Complications , 2014, Journal of pharmacy practice.

[41]  H. Heidbuchel,et al.  EuroEco (European Health Economic Trial on Home Monitoring in ICD Patients): a provider perspective in five European countries on costs and net financial impact of follow-up with or without remote monitoring , 2014, European heart journal.

[42]  M. Peller,et al.  Kardia Mobile applicability in clinical practice: A comparison of Kardia Mobile and standard 12-lead electrocardiogram records in 100 consecutive patients of a tertiary cardiovascular care center , 2013, Cardiology journal.

[43]  Renato Pietro Ricci,et al.  Telemedicine and cardiac implants: what is the benefit? , 2012, European heart journal.

[44]  C Michael Stein,et al.  Azithromycin and the risk of cardiovascular death. , 2012, The New England journal of medicine.

[45]  B. Kuhn,et al.  Thorough QT/QTc study of tocilizumab after single-dose administration at therapeutic and supratherapeutic doses in healthy subjects. , 2011, International journal of clinical pharmacology and therapeutics.

[46]  R. Schweikert,et al.  Efficacy and Safety of Automatic Remote Monitoring for Implantable Cardioverter-Defibrillator Follow-Up: The Lumos-T Safely Reduces Routine Office Device Follow-Up (TRUST) Trial , 2010, Circulation.

[47]  U. Moretti,et al.  Antimicrobials and the Risk of Torsades de Pointes , 2010, Drug safety.

[48]  A. Dreisbach,et al.  Randomized Dose-Ranging Controlled Trial of AQ-13, a Candidate Antimalarial, and Chloroquine in Healthy Volunteers , 2007, PLoS clinical trials.

[49]  I. Cygankiewicz,et al.  The Cardiac Safety of Chloroquine Phosphate Treatment in Patients with Systemic Lupus Erythematosus: The Influence on Arrhythmia, Heart Rate Variability and Repolarization Parameters , 2006, Lupus.

[50]  Sanjit Bagchi,et al.  Telemedicine in Rural India , 2006, PLoS medicine.

[51]  R. Costa,et al.  Cardiac damage from chronic use of chloroquine: a case report and review of the literature. , 2002, Arquivos brasileiros de cardiologia.

[52]  R. F. I. Smith,et al.  Governance , 2001, The Corporation as a Protagonist in Global History, c. 1550-1750.

[53]  L. Rimmer,et al.  Comparison of 2 methods of measuring the QT interval. , 1998, American journal of critical care : an official publication, American Association of Critical-Care Nurses.

[54]  L. Rimmer.  Bedside monitoring of the QT interval. , 1998, American journal of critical care : an official publication, American Association of Critical-Care Nurses.

[55]  Richard L. Verrier,et al.  ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiacmonitoring / telemetry , 2017 .

[56]  Janet Richards,et al.  Information governance. , 2006, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[57]  K. Jenpanich,et al.  [Drug administration]. , 1976, Thai journal of nursing.